Biotechnology company OncoSec Medical Incorporated (NASDAQ:ONCS) reported on Thursday the receipt of the US Food and Drug Administration's (FDA) Investigational New Drug (IND) application for the first-in-human Phase 1 trial for its CORVax12, a novel DNA-encodable vaccine against SARS-CoV-2, in partnership with Providence Cancer Institute, a part of Providence St Joseph Health.
The CORVax combines OncoSec's immuno-stimulant IL-12 expression platform, TAVO (tavokinogene telseplasmid), with a DNA-encodable stabilized trimeric SARS-CoV-2 spike glycoprotein developed at the National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID) and which has been licensed to OncoSec on a non-exclusive basis.
Under the terms of the agreement, Providence will begin a Phase 1, open-label study to evaluate the safety and immunogenicity of a plasmid encoding the SARS-CoV-2 spike protein alone or in combination with IL-12 (CORVax12, SARS-CoV-2 S glycoprotein plasmid DNA in combination with IL-12 plasmid) in up to 36 healthy volunteers.
In conjunction with the agreement, CORVax12 will be given as a prime and booster dose four weeks apart. The subjects will be subdivided in parallel age cohorts of 18-55 years old versus > 55 years old, added the company.
According to the companies, CORVax12 is the only DNA vaccine that uses an immune stimulant to promote an immune response against the SARS-CoV-2 virus. The CORVax vaccine approach combines the co-administration of TAVO (plasmid IL-12) with a DNA-encodable version of the SARS-CoV-2 spike or S glycoprotein to enhance immunogenicity of the component developed at NIAID Vaccine Research Center.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary